Press Release: Avantor(R) Announces Ludovic Brellier as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer

Dow Jones
04/24

RADNOR, Pa., April 23, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today announced that Ludovic Brellier will join the company as Executive Vice President, Bioscience & Medtech Products (BMP) & Chief Transformation Officer on May 1, 2026.

In this role, Mr. Brellier will be responsible for growing the BMP business and improving operational performance. He will also lead the Revival Management Office, driving transformation initiatives across the enterprise.

Mr. Brellier is an accomplished executive with deep operational experience across healthcare and strategic business transformation. He joins Avantor from Danaher, where he was most recently President of Cytiva's Hardware Solutions business, leading five business units responsible for early innovation through manufacturing and commercialization of services for the biopharma industry. While at Cytiva, Mr. Brellier previously served as President of Integrated Solutions & Services and VP Business Operations. He also led the effort to establish Cytiva as a standalone operating company within Danaher as well as the integration of Pall Life Sciences and Cytiva.

"Ludovic is a skilled operator who has a successful track record of growing bioprocessing businesses both organically and inorganically, and our BMP segment is a strong platform that has a lot of potential for growth under his leadership," said Emmanuel Ligner, Avantor's President and CEO. "As we execute Revival across our enterprise, Ludovic's past transformation and integration experience will be critical." Ligner concluded.

Mr. Brellier added, "Avantor's bioprocessing platform has leading product brands with rich legacies and strong customer preference. I look forward to leveraging my manufacturing and commercialization skills to enhance our operations and drive sustainable growth in the business by enabling the product brands to reach their full potential. The successful execution of Revival will be critical to the success of both Avantor's business segments," Brellier concluded.

Benoit Gourdier, current Executive Vice President of Avantor's BMP Segment, will stay with the company until on or before the end of 2026 to ensure a smooth transition.

About Avantor

Avantor$(R)$ is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.

Investor Relations Contact

Chris Fidyk

Vice President, Investor Relations

Avantor

Chris.Fidyk@avantorsciences.com

Global Media Contact

Eric Van Zanten

Head of External Communications

Avantor

610-529-6219

Eric.VanZanten@avantorsciences.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/avantor-announces-ludovic-brellier-as-executive-vice-president-bioscience--medtech-products-bmp--chief-transformation-officer-302752230.html

SOURCE Avantor and Financial News

 

(END) Dow Jones Newswires

April 23, 2026 17:05 ET (21:05 GMT)

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10